IOANNIS VAMVAKARIS | Precision Medicine | Best Researcher Award

Published on 11/06/202511/06/2025 by Top Pharmaceutical

IOANNIS VAMVAKARIS | Precision Medicine | Best Researcher Award

Dr. IOANNIS VAMVAKARIS, IATROPOLIS, Greece

Dr. Ioannis Vamvakaris is a distinguished Greek pathologist specializing in thoracic pathology. 🫁 He earned his MSc in Thoracic Oncology in 2013 and PhD in 2018 from Athens School of Medicine. 🎓 Since 2019, he has led the Pathology Department at Sotiria General Hospital. 🏥 He’s authored over 200 publications 📚 and co-developed Greece’s first AI software for pathology. 🤖 A reviewer for top journals (Elsevier, MDPI), he actively collaborates on global research in cancer, organoids, proteomics, and microbiome. 🌍 Recognized with the 2024 Best Researcher Award 🏆 and Sigma Xi membership, Dr. Vamvakaris continues to shape medical science with dedication and innovation.

Publication Profile

Google Scholar

Education

Dr. Ioannis Vamvakaris is a highly accomplished pathologist who began his medical journey at Sotiria General Hospital in Athens 🏥. Since 2008, he has served as a consultant in the pathology department, demonstrating unwavering dedication to thoracic pathology 🫁. He earned his MSc in Thoracic Oncology in 2013 and completed his PhD in 2018 from the Athens School of Medicine 🎓. Dr. Vamvakaris also pursued specialized training in Patient-Crisis-Emergency Management at the Berlin School of Economics 🇩🇪. His academic growth and professional excellence highlight his strong commitment to advancing medical knowledge and enhancing patient care globally 🌍.

Awards

Dr. Ioannis Vamvakaris has earned prestigious honors in recognition of his exceptional contributions to pathology and oncology research 🔬. In 2024, he was presented with the Best Researcher Award at the International Research Awards on Oncology and Cancer Research 🧬. That same year, he was inducted as an Associate Member of Sigma Xi 🧠—a globally respected scientific research honor society that recognizes excellence through nomination only. Additionally, he received the Trusted Reviewer Certificate in 2023 📄, reflecting his outstanding commitment to scientific publishing and peer evaluation. These accolades underscore his leadership and integrity in medical science 🌟.o

Research Focus

Dr. Ioannis Vamvakaris is a leading expert in thoracic pathology, with a strong research focus on lung cancer, molecular oncology, and immunopathology 🔬. His studies span non-small cell lung cancer (NSCLC), checkpoint inhibitor-induced sarcoidosis, and PD-1/PD-L1 immune responses 🧬. His collaborative work explores liquid biopsy biomarkers, xenograft models, and AI-assisted diagnostics 🤖. Passionate about translational research, he contributes to genomics, proteomics, fibrosis, and epigenetics in thoracic malignancies. His multidisciplinary efforts bridge clinical pathology and personalized medicine, advancing early diagnosis and targeted therapies 💉. Dr. Vamvakaris’ research enriches global understanding of lung diseases and thoracic oncology 🌍.

Publication Top Notes

Sarcoidosis-like reactions induced by checkpoint inhibitors

Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts

Epithelial–mesenchymal transition in non small-cell lung cancer

Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer

Sputum and BAL Clara cell secretory protein and surfactant protein D levels in asthma

DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection

Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy

Salivary inflammatory markers in tension type headache and migraine: the SalHead cohort study

Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic …

An immunohistochemical evaluation of the proteins W nt1 and glycogen synthase kinase (GSK)‐3β in invasive breast carcinomas

Pulmonary blastoma: a comprehensive overview of a rare entity

Preoperative mutational analysis of circulating tumor cells (CTCs) and plasma-cfDNA provides complementary information for early prediction of relapse: A pilot study in early …

juan iovanna | Personalized Medicine | Best Researcher Award

Published on 21/05/202521/05/2025 by Top Pharmaceutical

juan iovanna | Personalized Medicine | Best Researcher Award

Prof. Dr. juan iovanna, INSERM, France

Prof. Dr. Juan Iovanna è un medico e ricercatore internazionale esperto in oncologia, specializzato nello studio del carcinoma pancreatico. Laureato e dottorato all’Università di Buenos Aires, lavora in Francia dal 1991 presso l’INSERM, dove ha raggiunto il grado di Direttore di Ricerca di Classe Eccezionale. Co-dirige il gruppo “Biologia del cancro pancreatico” al CRCM di Marsiglia e presiede il Programma G7 Cancer. Fondatore di tre start-up biotecnologiche, ha pubblicato 472 articoli con oltre 43.500 citazioni 📚. La sua missione è migliorare la prognosi del tumore pancreatico attraverso ricerca e innovazione terapeutica.

Publication Profile

orcid

Education

Prof. Dr. Juan Iovanna began his academic journey with a degree in Medicine from the University of Buenos Aires, Argentina, in 1982. Driven by a passion for biomedical research, he pursued a Ph.D. in Biomedical Sciences at the same university, which he completed in 1986. 🧬 His doctoral thesis, titled “Meccanismi di regolazione della sintesi proteica in modelli cellulari di stress,” focused on the mechanisms regulating protein synthesis in cellular stress models. 🧪 This foundational work laid the groundwork for his future contributions to medical science and molecular biology.

Experience

🔬 Prof. Dr. Juan Iovanna has built an illustrious career in cancer research. In 1991, he began as a researcher at INSERM in France and was promoted to Research Director in 1993 and again in 1998. 🚀 In 2011, he achieved the prestigious title of Directeur de Recherche de Classe Exceptionnelle (DRCE). From 2011 to 2023, he served as Vice-Director of the Marseille Cancer Research Center (CRCM) and led its Translational Medicine Department. 🧫 He also directed the “Pancreatic Cancer Biology” group from 1999 to 2023. Since 2024, he co-directs this group with Dr. Nelson Dusetti and serves as Emeritus Research Director.

Distinctions and Awards

Prof. Dr. Juan Iovanna has received numerous prestigious awards and honors throughout his career. In 2017, he was awarded the Jean Valade Prize by the Fondation de France for his outstanding contributions to biomedical research. 🌍 In 2018, he received the RAICES Award from Argentina’s Ministry of Science, Technology, and Innovation. 🇫🇷 In 2021, the French Senate honored him with a commemorative medal. In 2023, he was named Honorary Professor at the National University Arturo Jauretche (UNAJ), and in 2024, he was recognized as a Distinguished and Honorary Member of the University of Buenos Aires.

Research Focus

Prof. Dr. Juan Iovanna’s research is centered on precision oncology, with a primary focus on pancreatic ductal adenocarcinoma (PDAC). His work integrates transcriptomics, drug resistance mechanisms, redox metabolism, and multi-omics modeling to uncover novel therapeutic vulnerabilities and biomarkers. He contributes to the development of RNA signatures (like GemPred) to predict chemotherapy response, and investigates KRAS inhibition and therapy-induced senescence as pathways to reverse drug resistance. His translational studies aim to optimize personalized treatment strategies for pancreatic cancer patients, bridging molecular insights with clinical application.

Publication Top Notes

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma

The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer

Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’

Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial

Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity

Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction

Mario Leporace | Personalized Medicine | Best Innovation Award

Published on 03/05/202503/05/2025 by Top Pharmaceutical

Mario Leporace | Personalized Medicine | Best Innovation Award

Prof. Dr. Mario Leporace, Hospital and University, Italy

Prof. Dr. Mario Leporace is a distinguished Clinical Radiologist at the Department of Nuclear Medicine and Theragnostics, “Mariano Santo” Hospital, Cosenza, Italy. With expertise in oncologic imaging, hybrid and molecular imaging, and cardiovascular radiology, he is renowned for his advanced diagnostic work using X-ray, CT, MRI, PET/CT, and SPECT/CT. He holds a Master’s in Interventional Oncology and has contributed to over 15 peer-reviewed publications. His professional journey spans top institutions in Rome and Cosenza, marking a career dedicated to innovation in radiology and nuclear medicine.

Publication Profile

Scopus

Education

Prof. Dr. Mario Leporace 🎓 is a distinguished expert in interventional oncology and radiology. In 2022, he earned a Master’s Degree in Interventional Oncology from Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, with a thesis on thermal ablation of bone metastases 🔥🦴. From 2001 to 2005, he completed his post-graduate certification in Radiology at the University of Rome “Tor Vergata” 🏥, graduating cum laude with a thesis on hybrid imaging 🧠📸. He also obtained his Degree in Medicine and Surgery from the same university (1995–2001), graduating with top honors and a thesis in vascular imaging 🫀🧬.

Experience

Prof. Dr. Mario Leporace 🩺 has an extensive career in radiology and nuclear medicine, showcasing over two decades of dedicated medical service. Since October 2017, he has been serving in the Department of Nuclear Medicine and Theragnostics at “Mariano Santo” Hospital in Cosenza, Italy ⚛️🏥. From May 2016 to September 2017, he worked at the Department of Radiology, “Annunziata” Hospital 🏨. Earlier, from March 2006 to April 2016, he contributed to the European Hospital in Rome, and concurrently, from November 2005 to April 2016, served at the Aurelia Hospital in Rome 🏛️🔬, strengthening his clinical expertise across institutions.

Research Focus

Prof. Dr. Mario Leporace focuses his research on Thermal Ablation with Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) 🔬🧠. His work bridges medical physics and oncological applications, exploring non-invasive treatments that use focused ultrasound energy to thermally ablate tumors with MRI precision guidance 🎯. This technique offers cutting-edge therapeutic possibilities in fields such as oncology, neurology, and women’s health 🧬💡. Prof. Leporace’s contributions advance both the clinical outcomes and technological innovation of MRgFUS, making him a key figure in image-guided therapy, minimally invasive surgery, and cancer treatment research .

Publication Top Notes

The Thermal Ablation with MRgFUS: From Physics to Oncological Applications

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Published on 22/04/202522/04/2025 by Top Pharmaceutical

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. 🏅 He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. 🎓 His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. 🎓 Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. 💊 He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. 🏆 This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. 💡 Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs

Zhi-Ming Shao | Precision Medicine | Best Researcher Award

Published on 16/04/202516/04/2025 by Top Pharmaceutical

Zhi-Ming Shao | Precision Medicine | Best Researcher Award

Prof. Zhi-Ming Shao, Fudan University Shanghai Cancer Center, China

Prof. Zhi-Ming Shao is a distinguished surgical oncologist and global leader in breast cancer research. A graduate of Shanghai Medical University, he chairs the Department of Breast Surgery at Fudan University Shanghai Cancer Center and directs its Breast Cancer Institute. With extensive postdoctoral experience in the U.S. and over 30 years of academic excellence, Prof. Shao has received numerous national honors, including the Chang Jiang Scholar and China’s Most Beautiful Doctor Award. His groundbreaking research, published in top journals like Nature Genetics and Cancer Cell, has significantly advanced precision oncology and breast cancer therapy worldwide.

Publication Profile

Scopus

Education

Prof. Zhi-Ming Shao began his medical journey at Shanghai Medical University, where he earned his Bachelor of Medicine (1980–1985). Driven by a passion for cancer treatment, he pursued a Residency in Surgical Oncology (1985–1990) at the prestigious Fudan University Shanghai Cancer Center. During this period, he also completed his Doctor of Medicine (M.D.) through a Postgraduate Course in Surgical Oncology (1987–1990) at Shanghai Medical University. His comprehensive education laid a strong foundation for his distinguished career in oncology, combining clinical expertise with academic excellence.

Experience

Prof. Zhi-Ming Shao has undergone extensive professional training and leadership roles in oncology. He began as a Postdoctoral Research Fellow (1990–1991) at Wake Forest University, followed by a role as Research Associate (1991–1995) at the University of Maryland Cancer Center. Returning to China, he became Associate Professor (1996–1998) and then Professor (1998–present) at Fudan University Shanghai Cancer Center. Since 2000, he has chaired the Department of Breast Surgery and became Director of the Breast Cancer Institute (2019–present). He also served as Chairman of the 8th Asian Breast Cancer Association (2010–2012) and is now Honorary Chairman of the China Anti-Cancer Association.

Awards

Prof. Zhi-Ming Shao has received numerous prestigious honors and awards throughout his career. In 1998, he was named one of the first batch of distinguished professors of the Chang Jiang Scholars Program. He was awarded the National Science Fund for Distinguished Young Scholars in 2001 and recognized as a Young and Middle-aged Expert with Outstanding Contributions by the Ministry of Health of China in 2004. His accomplishments include the National Prize of Science and Technology Progress (Grade II) in 2005, the National May Day Labor Medal in 2008, and the Chinese Physician Prize in 2020. He was also honored with the 2023 China’s Most Beautiful Doctor Award.

Research Focus

Prof. Zhi-Ming Shao’s research focuses on breast cancer, particularly in the areas of pathogenesis and treatment strategies. His work explores novel therapeutic approaches, such as targeting specific pathways involved in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, as well as developing targeted imaging agents for improved diagnosis. Prof. Shao has contributed significantly to understanding the molecular mechanisms of breast cancer progression and therapy resistance. His studies involve investigating genetic markers, tumor microenvironment interactions, and new treatment combinations. Overall, his research aims to improve clinical outcomes for breast cancer patients, especially in advanced or resistant cases.

Publication Top Notes

Breast cancer: pathogenesis and treatments

Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4

LINC01235 Promotes Clonal Evolution through DNA Replication Licensing-Induced Chromosomal Instability in Breast Cancer

Pilot Study of Nectin-4–Targeted PET Imaging Agent ⁶⁸Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human

Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial

The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer

O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progression

Symptoms Related to Brachial Plexus Neuropathy After Supraclavicular Irradiation and Boost in Breast Cancer

Prognostic value of metabolic signature on 18F-FDGuptake in breast cancer patients after radiotherapy

TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Published on 03/04/202503/04/2025 by Top Pharmaceutical

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Dr. Alessandra Tucci, ASST Spedali Civili di Brescia, Italy

Dr. Alessandra Tucci is an esteemed Italian hematologist and Director of the Hematology Unit at ASST Spedali Civili di Brescia. With over three decades of expertise, she specializes in lymphomas, particularly in elderly patients. She holds dual specializations in Allergology & Immunology (University of Florence) and Hematology (University of Milan). A key figure in national and international research, she has led multiple clinical trials and serves on prestigious scientific boards, including the Italian Lymphoma Foundation (FIL) and European Hematology Association (EHA). An accomplished author and peer reviewer, Dr. Tucci continues to advance hematological research.

Publication Profile

Scopus

Education

Dr. Alessandra Tucci 🎓 earned her Doctor of Medicine degree from the University of Brescia in 1987, specializing in Allergology, Immunology, and Hematology. 🩸 Her dual specialization underscores her deep expertise in blood disorders and immune-related conditions. 🏥 Passionate about advancing medical science, she further pursued a Master’s in Management applied to hematology, showcasing her leadership in clinical and research settings. 📚 With a strong foundation in both patient care and scientific innovation, Dr. Tucci continues to make significant contributions to the field, bridging the gap between medical research and practical healthcare solutions. 🔬✨

Experience

Dr. Alessandra Tucci 🔬 is a Principal Investigator in numerous national and international studies, focusing on hematology, particularly lymphomas and hematologic malignancies in elderly patients. 🩸 Her research impact is evident through an impressive H-index of 44 (Scopus) and 48 (Google Scholar), with over 9,792 citations. 📊 She has contributed as a Guest Editor for Special Issues in high-impact journals like Cancers and serves as a reviewer for prestigious publications such as Lancet Haematology and Blood Advances. 📖 Her dedication to advancing hematologic research continues to shape the field and improve patient outcomes worldwide.

Awards

Dr. Alessandra Tucci 🏆 has played a pivotal role in clinical trials (phases I-III), driving innovative treatments in hematology and significantly improving patient care. 🩸 Her contributions extend beyond research, as she actively shapes the scientific community through editorial work, peer reviews, and participation in prestigious scientific boards. 📖🔬 Recognized for her expertise and leadership, she is a respected thought leader whose work influences both clinical practice and future therapeutic advancements. 🌍✨ Through her dedication, Dr. Tucci continues to leave a lasting impact on the field of hematology, inspiring researchers and improving patient outcomes worldwide. 💡👩‍⚕️

Research Focus

Dr. Alessandra Tucci is a distinguished researcher specializing in hematology 🩸, with a focus on lymphomas 🦠, leukemias 🧬, and stem cell transplantation 🏥. Her work extensively explores invasive pulmonary aspergillosis in leukemia, mantle cell lymphoma prognosis, and the impact of radiotherapy on hematologic malignancies. She contributes to clinical trials, geriatric oncology assessments, and advanced imaging techniques like FDG PET/CT 📡 to improve diagnostic precision and treatment outcomes. Dr. Tucci’s research plays a critical role in optimizing chemoimmunotherapy 💉 and personalized medicine for hematologic disorders.

Publication Top Notes

Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda

Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[¹⁸F]FDG PET/CT in Advanced Mantle Cell Lymphoma

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome Medicine, (2023), 15, 1, (22), 10.1186/s13073-023-01173-8)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial

2-[¹⁸]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome

Georgina Pamela Coló | Gene Therapy | Best Researcher Award

Published on 03/04/202503/04/2025 by Top Pharmaceutical

Georgina Pamela Coló | Gene Therapy | Best Researcher Award

Dr. Georgina Pamela Coló, INIBIBB-CONICET, Argentina

Dr. Georgina Pamela Coló is a distinguished molecular biologist specializing in cancer research. She earned her Ph.D. in Molecular Biology from the University of Buenos Aires (2007, Summa Cum Laude) and holds an MS in Biotechnology from Quilmes National University. Currently a Scientific Researcher at CONICET’s Instituto de Investigaciones Bioquímicas (INIBIBB) in Argentina, she also leads a Max Planck Institute partner group. Her research focuses on cancer progression and therapeutic innovations. With extensive international experience in Germany, Spain, and the U.S., Dr. Coló has authored impactful publications in top-tier journals.

Publication Profile

Scopus

Education

Dr. Georgina Pamela Coló 🎓 is a distinguished molecular biologist with a Ph.D. from the University of Buenos Aires, School of Sciences (2003-2007), where she graduated summa cum laude (10/10) under the mentorship of Dr. M.A. Costas. Prior to her doctorate, she earned an M.S. in Biotechnology (8.74/10) from Quilmes National University (1998-2002). Her academic journey began with a B.Sc. in Science and Technology (1998-2000) and training as a Laboratory Technician 🔬. With a strong foundation in biotechnology and molecular biology, Dr. Coló has made significant contributions to scientific research and innovation. 🧬✨

Experience

Dr. Georgina Pamela Coló 🧬 is a dedicated cancer researcher currently serving as a Scientific Researcher at CONICET (2024-present) at the Instituto de Investigaciones Bioquímicas (INIBIBB), Argentina. She previously worked as an Assistant Researcher (2019-2024) under Dr. Curino. Since 2018, she has led a Max-Planck-Institute partner group 🇩🇪 with Dr. Prof. Reinhard Fässler. Her career includes research fellowships in Spain 🇪🇸 and Germany, as well as postdoctoral studies at INIBIBB, Max-Planck-Institute, and CIB-CSIC. With extensive experience in molecular medicine and cancer biology 🔬, Dr. Coló continues to make groundbreaking contributions to biomedical research. ✨

Awards

Dr. Georgina Pamela Coló 🏆 has received numerous prestigious awards for her outstanding contributions to biomedical research. In 2021, she won the Best Poster Award 🖼️ at the Reunión de Sociedades de Biociencias in Argentina. She was honored with the JCI TOYP Award (2020) for scientific and technological development. In 2019, she received the Lucio Cherny Award for interdisciplinary research 🧬. Her accolades include the Best Poster Award (2018), multiple CONICET fellowships 🎓, and the Max Planck postdoctoral fellowship (2013-2016). Dr. Coló’s impactful research continues to be recognized on both national and international levels.

Research Focus

Dr. Georgina Pamela Coló is a researcher specializing in nanomedicine 🧪, oncology 🎗️, and proteomics 🧬. Her work focuses on amorphous silica nanoparticles and their antitumor activity in triple-negative breast cancer cells 🏥. She also investigates the proteomic effects of hemin in breast cancer, exploring molecular pathways and therapeutic targets. Her research integrates nanotechnology 🏗️ and biochemistry to develop innovative cancer treatments. Through cutting-edge proteomic analysis, she contributes to personalized medicine and targeted drug delivery 🎯. Her studies are highly relevant to pharmaceutical sciences 💊 and biomedical research 🔬, advancing potential cancer therapies.

Publication Top Notes

Amorphous silica nanoparticles exhibit antitumor activity in triple-negative breast cancer cells

Proteomic analysis of the effect of hemin in breast cancer

Yu Liu | Drug Discovery and Development | Best Researcher Award

Published on 03/04/202503/04/2025 by Top Pharmaceutical

Yu Liu | Drug Discovery and Development | Best Researcher Award

Mr. Yu Liu, China Institute of Pharmaceutical Industry Co., Ltd, China

Dr. Liu Yu (b. January 11, 1981, Hengyang, Hunan) is a distinguished researcher and doctoral supervisor specializing in medicinal chemistry. He earned his Ph.D. from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (2011). Currently, he serves as Deputy Director at the China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center. He is also a standing committee member of the Health Economics Theory and Policy Committee. Dr. Liu plays a pivotal role in pharmaceutical research and technology transfer in China.

Publication Profile

Scopus

Education

Mr. Yu Liu pursued his education in Medicinal Chemistry 🧪 at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences 🎓. He was enrolled as a full-time student from September 2008 to July 2011 📅. During this period, he dedicated himself to advanced research in the field, ultimately earning a Doctorate degree 🎖️. His studies focused on the development of medicinal compounds and pharmaceutical innovations, contributing to the field of drug discovery and development 💊. With a strong academic foundation, Mr. Liu gained expertise in chemical synthesis and pharmacology, preparing him for a successful career in medicinal sciences 🔬.

Professional Leadership

Mr. Yu Liu serves as the Deputy Director 🏛️ at both the Technology Transfer Center, China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center 🔬. In these roles, he plays a pivotal part in advancing pharmaceutical and biotechnology research 💊. His leadership drives innovation in drug development and synthesis, ensuring progress in the field of medicinal chemistry 🧪. With his extensive expertise, Mr. Liu significantly contributes to technology transfer, regulatory advancements, and pharmaceutical innovation, reinforcing his influence in the global healthcare industry 🌍.

Experience

Mr. Yu Liu is an esteemed member of high-level academic committees 🏛️, including the Standing Committee of the Health Economics Theory and Policy Professional Committee under the Chinese Association of Health Economics 📊. His active participation in these organizations reflects his dedication to bridging scientific innovation and economic policy in healthcare 💡💰. By contributing to policy development and strategic decision-making, he plays a crucial role in shaping the future of health economics and pharmaceutical advancements 💊. His interdisciplinary expertise ensures a significant impact on both scientific research and economic frameworks, fostering innovation in healthcare systems 🌍.

Research Focus

Yu Liu’s research focuses on analytical chemistry, particularly in pharmaceutical analysis. His expertise lies in the development and validation of advanced chromatographic techniques, such as GC (Gas Chromatography) and HPLC-RID (High-Performance Liquid Chromatography with Refractive Index Detection). His work involves identifying and quantifying related substances in pharmaceutical compounds, including novel impurities in tetrabenazine. His contributions ensure drug purity, safety, and efficacy, making a significant impact on quality control and regulatory compliance in the pharmaceutical industry. His research bridges analytical chemistry and pharmaceutical sciences, advancing drug formulation and safety.

Publication Top Notes

GC and HPLC-RID method development and validation for the determination of twelve related substances, including several novel compounds in tetrabenazine

Michael Harrison | Precision Medicine | Best Researcher Award

Published on 28/03/202528/03/2025 by Top Pharmaceutical

Michael Harrison | Precision Medicine | Best Researcher Award

Dr. Michael Harrison, UCSF, United States

Dr. Michael Harrison is a pioneering pediatric surgeon and fetal therapy expert. 🎓 He earned his B.A. from Yale (1965) and M.D. from Harvard Medical School (1969), followed by extensive surgical training at Massachusetts General Hospital and fellowships in pediatric surgery. 🏥 He joined UCSF in 1978, where he became a Full Professor and founded the Fetal Treatment Center. 👶 His groundbreaking work in fetal surgery has earned him numerous accolades, including the Golden Plate Award and presidency of the International Fetal Medicine and Surgery Society. 🌍 Now Professor Emeritus at UCSF, he continues to shape the field of pediatric surgery. ✨

Publication Profile

Scopus

Education

Dr. Michael Harrison 🎓 began his academic journey at Yale University (1961-1965), earning a B.A. before pursuing his M.D. in Medicine at Harvard Medical School (1965-1969) 🏥. He completed his surgical residency at Massachusetts General Hospital (1969-1971) and advanced his expertise as a Postdoctoral Fellow in Allergy & Immunology at the National Institute of Allergy and Infectious Disease (1971-1973) 🧬. Returning to Massachusetts General, he served as a Senior Resident (1973-1974) and Chief Resident (1974-1975) 🔬. Further specializing, he completed fellowships in Pediatric Surgery at Rikshospitalet (1975-1976) 🇳🇴 and Children’s Hospital of Los Angeles (1976-1978) 👶🩺.

Experience

Dr. Michael Harrison 🏥 has been a Founding Member of the International Fetal Medicine and Surgery Society (1981-present) 👶 and has served as its President at the Annual Meeting (1989, 2006) 🎤. He has contributed as a Committee Member for the Medical Advisory Committee of the American Association of Tissue Banks (1993-present) 🧬 and chaired the Committee on Fetal Therapy at APSA (1994-1996) 🏥. A Board Member of the International Society of the Fetus as Patient (1997-present) 🌍, he also consults for the MOMS study (2003-present) 🤰. Since 2010, he has been Vice President of the California Academy of Medicine 📚.

Awards

Dr. Michael Harrison 🏅 has received numerous prestigious honors, including the Golden Plate Award (1982, 1988) 🏆, the William E. Ladd Medal (2010) 🏅, and the Lifetime Achievement Award (2011) 🌟 from the International Fetal Medicine and Surgery Society. He was elected to the Institute of Medicine (2009) 📜 and honored with the Denis Browne Gold Medal (2013) 🏵️. As a celebrated lecturer, he has delivered keynote addresses worldwide 🌍, including at the Nobel Minisymposium on Fetal Medicine (1998) 🎤. His groundbreaking contributions in pediatric surgery have earned him global recognition and lasting influence in the field.

Research Focus

Dr. Michael R. Harrison is a pioneering surgeon and researcher in pediatric surgery and fetal therapy 🏥👶. His work focuses on maternal-fetal surgery, particularly for conditions like esophageal atresia and diaphragmatic hernia. He has contributed to the development of magnetic compression anastomosis 🧲 and other innovative minimally invasive surgical devices 🔬. His research advances the treatment of complex congenital disorders and improves outcomes for newborns. With numerous publications, he has significantly impacted pediatric device clinical trials 📊. Dr. Harrison’s groundbreaking contributions continue to shape the future of pediatric and fetal surgical care 🚼✨.

Publication Top Notes

Pediatric Device Clinical Trials Activity: 1999–2022

Lessons Learned From the First-In-Human Compassionate Use of Connect-EA™ in Ten Patients With Esophageal Atresia

Evaluation of a Magnetic Compression Anastomosis for Jejunoileal Partial Diversion in Rhesus Macaques

Sonographic Predictors of Survival in Fetal Diaphragmatic Hernia

Beyond the gut: spectrum of magnetic surgery devices

The Rearing of Maternal–Fetal Surgery: The Maturation of a Field from Conception to Adulthood

The novel application of an emerging device for salvage of primary repair in high-risk complex esophageal atresia

Esophageal Magnetic Compression Anastomosis in Esophageal Atresia Repair: A PRISMA-Compliant Systematic Review and Comparison with a Novel Approach

An experimental study on long term outcomes after magnetic esophageal compression anastomosis in piglets

Novel device for endoluminal esophageal atresia repair: First-in-human experience

Randa El-Mofty | Nanomedicine | Best Researcher Award

Published on 13/02/202513/02/2025 by Top Pharmaceutical

Randa El-Mofty | Nanomedicine | Best Researcher Award

Dr Randa El-Mofty ,Cairo university, Egypt

👩‍⚕️ Dr. Randa El-Mofty is an accomplished ophthalmologist from Cairo University, Egypt 🇪🇬, with an M.D. in Ophthalmology (2013) and extensive training in cornea and oculoplasty. 👁️ She specializes in clinical electrophysiology of vision, pediatric ophthalmology, and strabismus. As an Associate Professor, she mentors students and residents while contributing to global research. 🧠🔬 Her work includes studies on diabetic retinopathy, nystagmus, and retinal dystrophies. Dr. El-Mofty is a member of prominent societies like ISCEV and EgSCRS. 🌐 Her passion for eye health is evident in her publications, presentations, and international collaborations. 🏥✨

Publication Profile

Google Scholar

Education

Dr. Randa El-Mofty, M.D. 🎓, is an accomplished ophthalmologist with a medical degree from Cairo University, Egypt. She earned her doctorate in 2013 with a thesis on the role of amniotic membrane transplant in reducing postoperative adhesions after strabismus reoperations 👁️🩺. She also holds a Master’s degree (2009) with a thesis on a simple method for spherical implant implantation. Dr. El-Mofty graduated with Excellence and Honors for her M.B.B.CH. degree 🏆 and achieved a remarkable 99.5% in her Thanaweya Amma. Fluent in French 🇫🇷, she passed the Examen Alliance Française with distinction. Her educational journey began at Collège de la Mère de Dieu 📖.

Clinical Expertise

Dr. Randa El-Mofty, M.D., is a dedicated ophthalmologist with extensive clinical experience, gained through her fellowship in oculoplasty and cornea specialties. 🌟👁️ She currently serves as an Associate Professor at Cairo University, where she excels in providing top-quality care in adult and pediatric ophthalmology. 🧒👓 Her passion for eye health and commitment to academic excellence have made her a respected figure in the field. With a patient-centered approach and a drive for continuous learning, Dr. El-Mofty contributes significantly to advancing ophthalmic knowledge and delivering exceptional care to patients of all ages. 📖

Teaching & Mentoring

Dr. Randa El-Mofty, M.D., is a dedicated educator and mentor with a strong focus on clinical electrophysiology of vision 👁️⚡. Passionate about advancing eye care, she has actively contributed to both undergraduate and postgraduate education 🎓📚. Her guidance has led to significant research projects exploring ocular disorders and pioneering treatment innovations 🔍💡. Through her work, Dr. El-Mofty continues to inspire future generations of vision specialists while promoting innovative diagnostic and therapeutic techniques. Her commitment to education and research plays a crucial role in enhancing the understanding and treatment of various eye conditions 👩‍⚕️🔬.

Presentations

Dr. Randa El-Mofty, M.D., is a distinguished expert in clinical electrophysiology of vision, actively contributing to national conferences and courses in Egypt 🇪🇬👁️. She has served as an instructor, moderator, and presenter at major events like the Kasr Al-Aini Ophthalmology Department Annual Meeting (2025) and Eye World Hospital CME courses (2024). Her insightful presentations cover topics like retinal dystrophy biomarkers, rod-cone dystrophy, and VEP applications. She engages in pediatric ophthalmology discussions at the Egyptian Ophthalmology Society and ESIO. Dr. El-Mofty’s dedication to advancing vision science underscores her impactful role in ophthalmology education and clinical practice 🎓🔍.

Research Focus

Dr. RMAM El-Mofty’s research primarily focuses on ophthalmology 👁️, particularly strabismus surgery, amniotic membrane transplantation, and ocular tissue healing 🧵. Her work explores the use of cryopreserved amniotic membranes in reducing adhesions and fibrosis during extraocular muscle surgeries 🐇🔬. She investigates different membrane orientations, long-term outcomes, and innovations in strabismus reoperations 🏥. Additionally, she studies ocular toxicology, including the effects of gold nanoparticles on eye health ⚛️. Recent work also covers orbital infarction syndrome and surgical outcomes in exotropia correction 🩺. Her research aims to improve surgical techniques and enhance postoperative recovery in ophthalmic procedures 👓🔍.